Last 12 months
Inside the activity.
0 purchase rows · 93 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 6 |
| Dec 2025 | 0 | 16 |
| Jan 2026 | 0 | 2 |
| Feb 2026 | 0 | 49 |
| Mar 2026 | 0 | 5 |
| Apr 2026 | 0 | 1 |
| May 2026 | 0 | 6 |
| Jun 2026 | 0 | 5 |
| Jul 2026 | 0 | 3 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 09, 2019 Filed Dec 10, 2019 21:49 UTC |
Sachdev AmitEVP, Chief Patient Officer
|
Exercise / conversionCommon Stock | 5,000 | $109.14 | $545,700.00 |
DisclosureSEC source: 0001209191-19-059883 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,416 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 26, 2019 Filed Nov 26, 2019 21:11 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
Exercise / conversionStock Option (Right to buy) · Derivative | 3,910 | $0.00 Strike: $187.53 | $0.00 |
DisclosureSEC source: 0001209191-19-058097 · doc4.xml · derivative · entry 3 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,945 Underlying: Common Stock · 3,910 shares Expires 2029-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/06/2019. Read SEC document |
| November 25, 2019 Filed Nov 26, 2019 21:11 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 3,910 | $219.37 | $857,736.70 |
DisclosureSEC source: 0001209191-19-058097 · doc4.xml · nonDerivative · entry 2 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,553 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. Read SEC document |
| November 25, 2019 Filed Nov 26, 2019 21:11 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
Exercise / conversionCommon Stock | 3,910 | $187.53 | $733,242.30 |
DisclosureSEC source: 0001209191-19-058097 · doc4.xml · nonDerivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,463 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 25, 2019 Filed Nov 26, 2019 21:12 UTC |
Kewalramani ReshmaEVP and CMO
|
Exercise / conversionStock Option (Right to buy) · Derivative | 4,692 | $0.00 Strike: $187.53 | $0.00 |
DisclosureSEC source: 0001209191-19-058099 · doc4.xml · derivative · entry 3 Kewalramani Reshma · CIK 0001735944 · EVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,334 Underlying: Common Stock · 4,692 shares Expires 2029-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/06/2019. Read SEC document |
| November 25, 2019 Filed Nov 26, 2019 21:12 UTC |
Kewalramani ReshmaEVP and CMO
|
SaleCommon Stock | 4,692 | $219.37 | $1,029,284.04 |
DisclosureSEC source: 0001209191-19-058099 · doc4.xml · nonDerivative · entry 2 Kewalramani Reshma · CIK 0001735944 · EVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,098 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1. Read SEC document |
| November 25, 2019 Filed Nov 26, 2019 21:12 UTC |
Kewalramani ReshmaEVP and CMO
|
Exercise / conversionCommon Stock | 4,692 | $187.53 | $879,890.76 |
DisclosureSEC source: 0001209191-19-058099 · doc4.xml · nonDerivative · entry 1 Kewalramani Reshma · CIK 0001735944 · EVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,790 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 25, 2019 Filed Nov 26, 2019 21:13 UTC |
Sachdev AmitEVP, Chief Patient Officer
|
Exercise / conversionStock Option (Right to buy) · Derivative | 5,000 | $0.00 Strike: $109.14 | $0.00 |
DisclosureSEC source: 0001209191-19-058101 · doc4.xml · derivative · entry 5 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,500 Underlying: Common Stock · 5,000 shares Expires 2025-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| November 25, 2019 Filed Nov 26, 2019 21:13 UTC |
Sachdev AmitEVP, Chief Patient Officer
|
SaleCommon Stock | 5,000 | $220.00 | $1,100,000.00 |
DisclosureSEC source: 0001209191-19-058101 · doc4.xml · nonDerivative · entry 2 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,416 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. Read SEC document |
| November 25, 2019 Filed Nov 26, 2019 21:13 UTC |
Sachdev AmitEVP, Chief Patient Officer
|
Exercise / conversionCommon Stock | 5,000 | $109.14 | $545,700.00 |
DisclosureSEC source: 0001209191-19-058101 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,416 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 19, 2019 Filed Nov 21, 2019 21:19 UTC |
Sachdev AmitEVP, Chief Patient Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $109.14 | $0.00 |
DisclosureSEC source: 0001209191-19-057609 · doc4.xml · derivative · entry 5 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,500 Underlying: Common Stock · 5,000 shares Expires 2025-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| November 19, 2019 Filed Nov 21, 2019 21:19 UTC |
Sachdev AmitEVP, Chief Patient Officer
|
SaleCommon Stock | 5,000 | $215.00 | $1,075,000.00 |
DisclosureSEC source: 0001209191-19-057609 · doc4.xml · nonDerivative · entry 2 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,416 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. Read SEC document |
| November 19, 2019 Filed Nov 21, 2019 21:19 UTC |
Sachdev AmitEVP, Chief Patient Officer
|
Exercise / conversionCommon Stock | 5,000 | $109.14 | $545,700.00 |
DisclosureSEC source: 0001209191-19-057609 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,416 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 19, 2019 Filed Nov 21, 2019 21:21 UTC |
LEIDEN JEFFREY MDirector · CEO & President
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 32,502 | $0.00 Strike: $131.89 | $0.00 |
DisclosureSEC source: 0001209191-19-057610 · doc4.xml · derivative · entry 8 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 32,502 shares Expires 2025-07-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Fully vested. Read SEC document |
| November 19, 2019 Filed Nov 21, 2019 21:21 UTC |
LEIDEN JEFFREY MDirector · CEO & President
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 64,032 | $0.00 Strike: $109.14 | $0.00 |
DisclosureSEC source: 0001209191-19-057610 · doc4.xml · derivative · entry 7 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 64,032 shares Expires 2025-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Fully vested. Read SEC document |
| November 19, 2019 Filed Nov 21, 2019 21:21 UTC |
LEIDEN JEFFREY MDirector · CEO & President
|
SaleCommon Stock | 10,615 | $212.75 | $2,258,341.25 |
DisclosureSEC source: 0001209191-19-057610 · doc4.xml · nonDerivative · entry 5 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,346 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $212.75 (range $212.30 to $212.97). Read SEC document |
| November 19, 2019 Filed Nov 21, 2019 21:21 UTC |
LEIDEN JEFFREY MDirector · CEO & President
|
SaleCommon Stock | 23,033 | $211.43 | $4,869,867.19 |
DisclosureSEC source: 0001209191-19-057610 · doc4.xml · nonDerivative · entry 4 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,961 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $211.43 (range $211.08 to $211.97). Read SEC document |
| November 19, 2019 Filed Nov 21, 2019 21:21 UTC |
LEIDEN JEFFREY MDirector · CEO & President
|
SaleCommon Stock | 62,886 | $210.41 | $13,231,843.26 |
DisclosureSEC source: 0001209191-19-057610 · doc4.xml · nonDerivative · entry 3 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,994 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $210.41 (range $210.06 to $210.83). F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| November 19, 2019 Filed Nov 21, 2019 21:21 UTC |
LEIDEN JEFFREY MDirector · CEO & President
|
Exercise / conversionCommon Stock | 32,502 | $131.89 | $4,286,688.78 |
DisclosureSEC source: 0001209191-19-057610 · doc4.xml · nonDerivative · entry 2 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,880 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 19, 2019 Filed Nov 21, 2019 21:21 UTC |
LEIDEN JEFFREY MDirector · CEO & President
|
Exercise / conversionCommon Stock | 64,032 | $109.14 | $6,988,452.48 |
DisclosureSEC source: 0001209191-19-057610 · doc4.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,378 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 18, 2019 Filed Nov 19, 2019 21:12 UTC |
LEIDEN JEFFREY MDirector · CEO & President
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 1,493 | $0.00 Strike: $131.89 | $0.00 |
DisclosureSEC source: 0001209191-19-057137 · doc4.xml · derivative · entry 13 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,502 Underlying: Common Stock · 1,493 shares Expires 2025-07-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| November 18, 2019 Filed Nov 19, 2019 21:12 UTC |
LEIDEN JEFFREY MDirector · CEO & President
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 2,941 | $0.00 Strike: $109.14 | $0.00 |
DisclosureSEC source: 0001209191-19-057137 · doc4.xml · derivative · entry 12 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,032 Underlying: Common Stock · 2,941 shares Expires 2025-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| November 18, 2019 Filed Nov 19, 2019 21:12 UTC |
LEIDEN JEFFREY MDirector · CEO & President
|
SaleCommon Stock | 1,493 | $210.00 | $313,530.00 |
DisclosureSEC source: 0001209191-19-057137 · doc4.xml · nonDerivative · entry 8 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,346 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. Read SEC document |
| November 18, 2019 Filed Nov 19, 2019 21:12 UTC |
LEIDEN JEFFREY MDirector · CEO & President
|
Exercise / conversionCommon Stock | 1,493 | $131.89 | $196,911.77 |
DisclosureSEC source: 0001209191-19-057137 · doc4.xml · nonDerivative · entry 7 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,839 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 18, 2019 Filed Nov 19, 2019 21:12 UTC |
LEIDEN JEFFREY MDirector · CEO & President
|
SaleCommon Stock | 2,941 | $210.00 | $617,610.00 |
DisclosureSEC source: 0001209191-19-057137 · doc4.xml · nonDerivative · entry 6 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,346 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. Read SEC document |
| November 18, 2019 Filed Nov 19, 2019 21:12 UTC |
LEIDEN JEFFREY MDirector · CEO & President
|
Exercise / conversionCommon Stock | 2,941 | $109.14 | $320,980.74 |
DisclosureSEC source: 0001209191-19-057137 · doc4.xml · nonDerivative · entry 5 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,287 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 18, 2019 Filed Nov 20, 2019 21:10 UTC |
MCGLYNN MARGARET GDirector
|
GiftCommon Stock | 239 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-057431 · doc4.xml · nonDerivative · entry 1 MCGLYNN MARGARET G · CIK 0001215126 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,885 F1 · shares: This transaction represents a gift/charitable donation effective November 18, 2019, in which no value was received in return. Read SEC document |
| November 15, 2019 Filed Nov 19, 2019 21:07 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 60 | $205.95 | $12,357.00 |
DisclosureSEC source: 0001209191-19-057119 · doc4.xml · nonDerivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,553 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. Read SEC document |
| November 15, 2019 Filed Nov 19, 2019 21:09 UTC |
Arbuckle Stuart AEVP\Chief Commercial Officer
|
SaleCommon Stock | 19 | $205.95 | $3,913.05 |
DisclosureSEC source: 0001209191-19-057126 · doc4.xml · nonDerivative · entry 1 Arbuckle Stuart A · CIK 0001557290 · EVP\Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,240 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. Read SEC document |
| November 15, 2019 Filed Nov 19, 2019 21:11 UTC |
Kewalramani ReshmaEVP and CMO
|
SaleCommon Stock | 61 | $205.95 | $12,562.95 |
DisclosureSEC source: 0001209191-19-057132 · doc4.xml · nonDerivative · entry 1 Kewalramani Reshma · CIK 0001735944 · EVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,098 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1. Read SEC document |
| November 15, 2019 Filed Nov 19, 2019 21:12 UTC |
LEIDEN JEFFREY MDirector · CEO & President
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 1,683 | $0.00 Strike: $131.89 | $0.00 |
DisclosureSEC source: 0001209191-19-057137 · doc4.xml · derivative · entry 11 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,995 Underlying: Common Stock · 1,683 shares Expires 2025-07-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| November 15, 2019 Filed Nov 19, 2019 21:12 UTC |
LEIDEN JEFFREY MDirector · CEO & President
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 3,317 | $0.00 Strike: $109.14 | $0.00 |
DisclosureSEC source: 0001209191-19-057137 · doc4.xml · derivative · entry 10 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,973 Underlying: Common Stock · 3,317 shares Expires 2025-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| November 15, 2019 Filed Nov 19, 2019 21:12 UTC |
LEIDEN JEFFREY MDirector · CEO & President
|
SaleCommon Stock | 1,683 | $210.00 | $353,430.00 |
DisclosureSEC source: 0001209191-19-057137 · doc4.xml · nonDerivative · entry 4 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,346 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. Read SEC document |
| November 15, 2019 Filed Nov 19, 2019 21:12 UTC |
LEIDEN JEFFREY MDirector · CEO & President
|
Exercise / conversionCommon Stock | 1,683 | $131.89 | $221,970.87 |
DisclosureSEC source: 0001209191-19-057137 · doc4.xml · nonDerivative · entry 3 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,029 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 15, 2019 Filed Nov 19, 2019 21:12 UTC |
LEIDEN JEFFREY MDirector · CEO & President
|
SaleCommon Stock | 3,317 | $210.00 | $696,570.00 |
DisclosureSEC source: 0001209191-19-057137 · doc4.xml · nonDerivative · entry 2 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,346 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. Read SEC document |
| November 15, 2019 Filed Nov 19, 2019 21:12 UTC |
LEIDEN JEFFREY MDirector · CEO & President
|
Exercise / conversionCommon Stock | 3,317 | $109.14 | $362,017.38 |
DisclosureSEC source: 0001209191-19-057137 · doc4.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,663 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 15, 2019 Filed Nov 19, 2019 21:15 UTC |
Parini MichaelEVP, CL&AO
|
SaleCommon Stock | 84 | $205.95 | $17,299.80 |
DisclosureSEC source: 0001209191-19-057142 · doc4.xml · nonDerivative · entry 1 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,003 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. Read SEC document |
| November 15, 2019 Filed Nov 19, 2019 21:16 UTC |
Sachdev AmitEVP, Chief Patient Officer
|
SaleCommon Stock | 57 | $205.95 | $11,739.15 |
DisclosureSEC source: 0001209191-19-057148 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,416 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. Read SEC document |
| November 15, 2019 Filed Nov 19, 2019 21:17 UTC |
Tatsis OuraniaSVP, CRO
|
SaleCommon Stock | 5 | $205.95 | $1,029.75 |
DisclosureSEC source: 0001209191-19-057152 · doc4.xml · nonDerivative · entry 1 Tatsis Ourania · CIK 0001789815 · SVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,252 F1 · kind: Transaction made pursuant to Ms. Tatsis' company-approved trading plan under Rule 10b5-1. Read SEC document |
| November 13, 2019 Filed Nov 15, 2019 21:03 UTC |
Arbuckle Stuart AEVP\Chief Commercial Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 8,560 | $0.00 Strike: $155.57 | $0.00 |
DisclosureSEC source: 0001209191-19-056706 · doc4.xml · derivative · entry 4 Arbuckle Stuart A · CIK 0001557290 · EVP\Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,006 Underlying: Common Stock · 8,560 shares Expires 2028-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests in 16 quarterly installments from 2/6/2018. Read SEC document |
| November 13, 2019 Filed Nov 15, 2019 21:03 UTC |
Arbuckle Stuart AEVP\Chief Commercial Officer
|
SaleCommon Stock | 8,560 | $205.57 | $1,759,679.20 |
DisclosureSEC source: 0001209191-19-056706 · doc4.xml · nonDerivative · entry 2 Arbuckle Stuart A · CIK 0001557290 · EVP\Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,240 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company-approved trading plan under Rule 10b5-1. Read SEC document |
| November 13, 2019 Filed Nov 15, 2019 21:03 UTC |
Arbuckle Stuart AEVP\Chief Commercial Officer
|
Exercise / conversionCommon Stock | 8,560 | $155.57 | $1,331,679.20 |
DisclosureSEC source: 0001209191-19-056706 · doc4.xml · nonDerivative · entry 1 Arbuckle Stuart A · CIK 0001557290 · EVP\Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 13, 2019 Filed Nov 15, 2019 21:05 UTC |
Parini MichaelEVP, CL&AO
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 4,892 | $0.00 Strike: $155.57 | $0.00 |
DisclosureSEC source: 0001209191-19-056709 · doc4.xml · derivative · entry 3 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,006 Underlying: Common Stock · 4,892 shares Expires 2028-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests in 16 quarterly installments from 2/6/2018. Read SEC document |
| November 13, 2019 Filed Nov 15, 2019 21:05 UTC |
Parini MichaelEVP, CL&AO
|
SaleCommon Stock | 4,892 | $205.50 | $1,005,306.00 |
DisclosureSEC source: 0001209191-19-056709 · doc4.xml · nonDerivative · entry 2 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,003 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. Read SEC document |
| November 13, 2019 Filed Nov 15, 2019 21:05 UTC |
Parini MichaelEVP, CL&AO
|
Exercise / conversionCommon Stock | 4,892 | $155.57 | $761,048.44 |
DisclosureSEC source: 0001209191-19-056709 · doc4.xml · nonDerivative · entry 1 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,895 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 13, 2019 Filed Nov 15, 2019 21:07 UTC |
Tatsis OuraniaSVP, CRO
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 2,853 | $0.00 Strike: $155.57 | $0.00 |
DisclosureSEC source: 0001209191-19-056713 · doc4.xml · derivative · entry 3 Tatsis Ourania · CIK 0001789815 · SVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,669 Underlying: Common Stock · 2,853 shares Expires 2028-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vests in 16 quarterly installments from 2/6/2018. Read SEC document |
| November 13, 2019 Filed Nov 15, 2019 21:07 UTC |
Tatsis OuraniaSVP, CRO
|
SaleCommon Stock | 2,853 | $205.59 | $586,548.27 |
DisclosureSEC source: 0001209191-19-056713 · doc4.xml · nonDerivative · entry 2 Tatsis Ourania · CIK 0001789815 · SVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,252 F1 · kind: Transaction made pursuant to Ms. Tatsis' company-approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $205.59 (range $205.57 to $205.76). F3 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| November 13, 2019 Filed Nov 15, 2019 21:07 UTC |
Tatsis OuraniaSVP, CRO
|
Exercise / conversionCommon Stock | 2,853 | $155.57 | $443,841.21 |
DisclosureSEC source: 0001209191-19-056713 · doc4.xml · nonDerivative · entry 1 Tatsis Ourania · CIK 0001789815 · SVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,105 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 08, 2019 Filed Nov 13, 2019 21:08 UTC |
Kewalramani ReshmaEVP and CMO
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 509 | $0.00 Strike: $155.57 | $0.00 |
DisclosureSEC source: 0001209191-19-056327 · doc4.xml · derivative · entry 3 Kewalramani Reshma · CIK 0001735944 · EVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,587 Underlying: Common Stock · 509 shares Expires 2028-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests in 16 quarterly installments from 2/6/2018. Read SEC document |
| November 08, 2019 Filed Nov 13, 2019 21:08 UTC |
Kewalramani ReshmaEVP and CMO
|
SaleCommon Stock | 509 | $199.00 | $101,291.00 |
DisclosureSEC source: 0001209191-19-056327 · doc4.xml · nonDerivative · entry 2 Kewalramani Reshma · CIK 0001735944 · EVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,098 F1 · kind: Transaction made pursuant to Dr. Kewalramani's company-approved trading plan under Rule 10b5-1. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.